| 216.25 3.32 (1.56%) | 06-02 15:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 256.97 | 1-year : | 300.14 |
| Resists | First : | 220 | Second : | 256.97 |
| Pivot price | 213.1 |
|||
| Supports | First : | 201.92 | Second : | 190.75 |
| MAs | MA(5) : | 216.05 |
MA(20) : | 210.73 |
| MA(100) : | 214.54  |
MA(250) : | 210.63 |
|
| MACD | MACD : | 2.4 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 74.2 |
D(3) : | 80.2 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 239.13 | Low : | 175.99 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABBV ] has closed below upper band by 29.4%. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 216.59 - 218.05 | 218.05 - 219.26 |
| Low: | 208.72 - 210.14 | 210.14 - 211.31 |
| Close: | 210.91 - 213.21 | 213.21 - 215.13 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Tue, 02 Jun 2026
AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO® - Insider Monkey
Tue, 02 Jun 2026
Is AbbVie Inc. (ABBV) Expanding Its Oncology Pipeline With New BPDCN Treatment Approval? - Yahoo Finance
Tue, 02 Jun 2026
AbbVie (ABBV) Secures EU Approval for Aquipta as Migraine Treatm - GuruFocus
Mon, 01 Jun 2026
AbbVie Inc. (ABBV) Stock Analysis: Evaluating a 16% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Fri, 29 May 2026
AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Fri, 29 May 2026
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? - Barchart.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,770 (M) |
| Shares Float | 1,760 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 22,590 (K) |
| Shares Short P.Month | 21,850 (K) |
| EPS | 2.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.77 |
| Profit Margin | 5.7 % |
| Operating Margin | 32.1 % |
| Return on Assets (ttm) | 10 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12.3 % |
| Gross Profit (p.s.) | 25.56 |
| Sales Per Share | 35.49 |
| EBITDA (p.s.) | 16.9 |
| Qtrly Earnings Growth | -46.3 % |
| Operating Cash Flow | 21,220 (M) |
| Levered Free Cash Flow | 20,810 (M) |
| PE Ratio | 105.21 |
| PEG Ratio | 0.6 |
| Price to Book value | -57.22 |
| Price to Sales | 6.07 |
| Price to Cash Flow | 17.99 |
| Dividend | 1.73 |
| Forward Dividend | 0 |
| Dividend Yield | 0.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|